Clinical trial NCT04677049: Study of Niacin in Glioblastoma
Official title: A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma Receiving Concurrent Radiotherapy and Temozolomide Followed by Monthly Temozolomide
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Keywords: Glioblastoma
Lead sponsor: AHS Cancer Control Alberta
Sponsor class: OTHER
Collaborators: name: Tom Baker Cancer Centre
First posted: 2020-12-21
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single institution Phase I-II study to evaluate the tolerability and Maximum Tolerated Dose (MTD) (Phase I) and efficacy (Phase II) of adding Niacin CRT™ to standard first line treatment (concurrent Radiation Therapy (RT) and Temozolomide (TMZ) following by monthly TMZ - AKA Stupp protocol) in patients with newly diagnosed glioblastoma isocitrate dehydrogenase (IDH) wild type.

Detailed description: During the Phase I stage Niacin CRT™ dose will be escalated every 4 weeks until the maximum tolerated dose (MTD) is determined. The MTD dose will be prescribed to patients during the Phase II stage.

During the Phase I study a sample of blood at baseline, at each level dose of Niacin CRT™, and every two months during the maintenance phase while on Niacin CRTTM will be sent to a lab to evaluate the peripheral activity of Niacin CRT™ in innate immune system cells. These samples will be taken at the time of routine standard of care lab work.

Based on prior clinical trials evaluating niacin extended release formulation for the management of dyslipidaemias there is vast experience on dose escalation of niacin. One of the main side effects is flushing that is ameliorated by escalating doses in intervals no shorter than 4 weeks and usually decreases with time.

Following this schema, there is no increase in dose coinciding with TMZ while administered in a 5/28 days schedule (given daily for 5 days of each 28-day cycle). This will not only improve tolerance but also will allow us to differentiate potential adverse events from chemotherapy from the ones from Niacin CRT™.

Eligibility criteria: Inclusion Criteria:

* Adults, 18 years old to 75 years old inclusive.
* New diagnoses of glioblastoma IDH wild type.
* ECOG 0-2 (Appendix I).
* Candidates for concurrent standard first line treatment according to their Neuro-Oncologist and Radiotherapy Oncologist after maximal safe debulking neurosurgery. Patients that only had biopsy are included as long as pathology confirms the diagnoses and it is considered the maximal safe procedure for that patient.
* Adequate hematological, renal and hepatic function (see details in Section 4.1 of the protocol).
* Absence of known human immunodeficiency virus (HIV) infection, chronic hepatitis B or hepatitis C infection.
* Absence of any other serious medical condition according to the medical judgment of the Qualified Investigator prior to registration.
* Absence of any medical condition, which could interfere with oral medication intake.
* Signed informed consent.
* Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre.
* Women/men of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion Criteria:

* Glioblastoma, IDH-mutant.
* Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years. Additionally, any low grade or low risk malignancy not requiring treatment will not exclude a patient from participation in the trial.
* Known hypersensitivity to niacin.
* Inability to provide informed consent.
* Active liver disease or unexplained persistent elevations of serum transaminases.
* Active peptic ulcer or active gastrointestinal bleeding.
* Unstable angina or myocardial infarction within 6 months.
* Symptomatic gout.
* Patients on 3-hydroxy-3-methylglutaryl-coenzyme (HMG-COA reductase) inhibitors that cannot discontinue them at least 2 weeks before starting Niacin CRT™.
* Any prior systemic treatment for glioblastoma (standard, evidence based or experimental) or radiotherapy/radiosurgery.
* Individuals with MRI non-compatible metal in the body, or unable to undergo MRI procedures including allergy to gadolinium.
* Patients unfit for any treatment component, including contraindications for radiotherapy or Connective Tissue Disease.
* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
* Has known psychiatric or substance abuse disorders that would interfere with compliance with the requirements of the trial.
* Pregnant, breast-feeding, unable and/or unwilling to use contraception methods.

Primary outcomes:
measure: Determining the Maximum Tolerated Dose
timeFrame: Up to 24 weeks after registration onto the study
measure: Evaluating if Niacin CRT Improves Glioblastoma Survival Rates
timeFrame: 6 months after determining the maximum tolerated dose which can last up to 24 weeks after registration onto the study
Secondary outcomes:
measure: Effect of Niacin CRT in Peripheral Monocytes
timeFrame: From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.
measure: Response Rate Associated with Niacin
timeFrame: From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.
measure: Overall Survival Rate Associated with Niacin
timeFrame: From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.
measure: Quality of Life While on Study using EORTC QLQ-C30 Questionnaires
timeFrame: From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.
measure: Quality of Life While on Study using EORTC BN-20 Questionnaires
timeFrame: From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
Study officials:
affiliation: Tom Baker Cancer Centre
name: Gloria Roldan Urgoiti, MD
role: PRINCIPAL_INVESTIGATOR
References: